Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Carnitine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.52 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.42 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.95 |
| ▸ | CPT2 | P23786 | 2/20 | 0.59 |
| ▸ | CPT1A | P50416 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CRAT | P43155 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 2/20 | 0.42 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| D-Carnitine SCHEMBL6855781 | 1.00 | SLC22A16 (0.95) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| Levocarnitine SCHEMBL388330 | 1.00 | SLC22A16 (0.95) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| Levocarnitine SCHEMBL9633322 | 1.00 | SLC22A16 (0.95) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| Carnitine SCHEMBL10631240 | 1.00 | SLC22A16 (0.95) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| Carnitine SCHEMBL10435820 | 1.00 | SLC22A16 (0.95) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| Carnitine SCHEMBL10633747 | 0.98 | SLC22A16 (0.91) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| Levocarnitine SCHEMBL21970 | 0.98 | SLC22A16 (1.00) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| D-Carnitine SCHEMBL94286 | 0.98 | SLC22A16 (1.00) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| Carnitine SCHEMBL21971 | 0.98 | SLC22A16 (1.00) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| Carnitine SCHEMBL1813524 | 0.98 | SLC22A16 (1.00) | SLC22A16CPT2CPT1AMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1821 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4204609-B1 | COMPOSITIONS AND METHODS FOR THE ELECTRODEPOSITION OF NANOTWINNED COPPER | MACDERMID ENTHONE INC (US) | 2026-05-27 | — | — | EP | claimed |
| CN-122005509-A | High-efficiency absorption ergothioneine orosol film and preparation method thereof | 上海欣峰健康科技有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-12600953-B2 | Compositions and method for establishing organoid cultures from cryogenically preserved tissue | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-04-14 | — | — | US | claimed |
| US-20260078517-A1 | COMPOSITION AND METHOD FOR NANOTWINNED COPPER FORMATION | MACDERMID ENTHONE INC (US) | 2026-03-19 | — | — | US | claimed |
| CN-121583971-A | Application of carnitine hydrochloride in zinc-bromine flow battery electrolyte, zinc-bromine flow battery electrolyte and battery | 北京化工大学 | 2026-02-27 | — | — | CN | claimed |
| EP-4687485-A1 | NOVEL COMBINATIONS COMPRISING KONJAC MANNAN, THEIR COMPOSITIONS AND USES THEREOF | Vivatis Pharma GmbH (DE) | 2026-02-11 | — | — | EP | claimed |
| EP-4687486-A1 | NOVEL COMBINATIONS COMPRISING KONJAC MANNAN, THEIR COMPOSITIONS AND USES THEREOF | Vivatis Pharma GmbH (DE) | 2026-02-11 | — | — | EP | claimed |
| US-20260000673-A1 | BRAIN HEALTH SUPPLEMENT | MAGOOLA MATTHIAS (UG) | 2026-01-01 | — | — | US | claimed |
| US-12378529-B2 | Method for culturing colorectal cancer solid tumor primary cells and colorectal cancer ascites primary tumor cells and supporting reagents | GENEX HEALTH CO., LTD (CN) | 2025-08-05 | — | — | US | claimed |
| CN-222980273-U | High-power high-frequency inductor with auxiliary heat dissipation function | 江西省高新超越精密电子有限公司 | 2025-06-13 | — | — | CN | claimed |
| US-5158770-A | Mixture of organic solvent, alcohol, and nitrogen containing compound | FREUND INDUSTRIAL CO., LTD. (JP) | 1992-10-27 | — | — | US | claimed |
| EP-0416583-A1 | Method for the preparation of crotonobetaine hydrochloride | LONZA AG (CH) | 1991-03-13 | — | — | EP | claimed |
| US-4933490-A | Process for the preparation of L(-)carnitine hydrochloride and of L(-)carnitine inner salt | ISOM S.P.A. (IT) | 1990-06-12 | — | — | US | claimed |
| EP-0141408-B1 | PROCESS FOR THE PREPARATION OF L(-)CARNITINE HYDROCHLORIDE AND OF L(-)CARNITINE INNER SALT | ISOM S.p.A. (IT) | 1989-08-23 | — | — | EP | claimed |
| EP-0207437-B1 | NEW CARNITINE SALTS PARTICULARLY SUITABLE FOR ORAL USE | BIORESEARCH S.p.A. (IT) | 1988-08-24 | — | — | EP | claimed |
| US-4673534-A | ALKYLSULFONATE SALTS, USEFUL IN TREATMENT OF MYOPATHY | BIORESEARCH SPA (IT) | 1987-06-16 | — | — | US | claimed |
| EP-0207437-A1 | New Carnitine salts particularly suitable for oral use | BIORESEARCH S.p.A. (IT) | 1987-01-07 | — | — | EP | claimed |
| US-4021480-A | Process for the production of carnitine | LONZA LTD. (CH) | 1977-05-03 | — | — | US | claimed |
| US-4018821-A | Process for the production of carnitine | LONZA LTD. (CH) | 1977-04-19 | — | — | US | claimed |
| US-3969406-A | Process for the production of carnitine | LONZA LTD. (CH) | 1976-07-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600953-B2 | Compositions and method for establishing organoid cultures from cryogenically preserved tissue | BMP4, DSP, WNT3A | HRH1 3329/4885CA2 1828/4885SLC22A16 4303/4885 |
| US-20260078517-A1 | COMPOSITION AND METHOD FOR NANOTWINNED COPPER FORMATION | AOC2, HCN2, STMN2 | HRH1 1503/4885CA2 1519/4885SLC22A16 1595/4885 |
| US-20260000673-A1 | BRAIN HEALTH SUPPLEMENT | SNCA, SLC19A2, FABP2 | HRH1 865/4885CA2 3354/4885SLC22A16 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.